LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today that it has raised $10 million of its Series C Preferred equity offering. “We are very pleased to have the investor support allowing us to reach $10 million in preferred stock sold out of our $15 million offering,” stated Steve Kemper, DermTech’s Chief Financial Officer. “This goal is especially important as we achieved the milestone with our first institutional investment from RTW Investments along with the many private investors that have funded DermTech thus far,” he added. The company is using the proceeds to continue to expand its sales force and bring its new skin cancer products to the market in 2018.
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: dermtech.com.